2 recruiting, 1 completed, 1 not yet recruiting. 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Mediastinal Lymphoma: new trials by email Literature Review of Mediastinal Lymphoma trials Research Report on Mediastinal Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proton Therapy for Mediastinal Lymphoma (PROMLY) Proton therapy - Mediastinal Lymphoma, Hodgkin Disease Lymphoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 139 | 2026-05-01 | 2026-09-14 |
| Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation Standard treatment protocol with combined chemoradiation - Mediastinal Lymphoma, Hodgkin Lymphoma | Not yet recruiting | Chang Gung Memorial Hospital | 50 | 2023-05-01 | 2023-04-18 | |
| Registry Study of Proton Radiotherapy in Lymphoma Assesment of Effectiveness and side effects - Mediastinal Lymphoma | Recruiting | University Hospital Heidelberg | 200 | 2018-08-01 | 2026-04-29 | |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
Hodgkin Disease (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Burkitt Lymphoma (1) · Cardiotoxicity (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Cardiovascular Diseases (2) · Lymphoma, Non-Hodgkin (2) · Blood Protein Disorders (1) · Chemically-Induced Disorders (1) · DNA Virus Infections (1) · Drug-Related Side Effects and Adverse Reactions (1) · Epstein-Barr Virus Infections (1) · Heart Diseases (1)
Proton Therapy (1) · ibrutinib (1) · pembrolizumab (1)
Chang Gung Memorial Hospital (1) · Copenhagen University Hospital, Rigshospitalet (1) · Kami Maddocks (1) · University Hospital Heidelberg (1)
Denmark (1) · Germany (1) · Taiwan (1) · United States (1)
P30CA016058 (1)